Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xenetic Biosciences (NASDAQ: XBIO) has announced a significant collaboration with The Scripps Research Institute to advance its systemic DNase-based oncology program, aimed at treating pancreatic carcinoma and other solid tumors. This partnership will enhance the development of the DNase platform, which targets neutrophil extracellular traps (NETs), implicated in cancer progression and therapeutic resistance. Xenetic plans to initiate a first-in-human study assessing the DNase in combination with immune checkpoint inhibitors or chemotherapy. Furthermore, the agreement allows Xenetic to acquire an exclusive license for any new intellectual property resulting from the research. This collaboration is seen as a critical step towards creating much-needed therapies for challenging cancer indications.
Xenetic Biosciences (NASDAQ: XBIO) reported significant developments in its annual results for 2022. The company is focusing on the DNase oncology platform, which targets neutrophil extracellular traps to improve cancer therapies. The DNase program is progressing towards Phase 1 clinical development and aims to provide treatments for pancreatic carcinoma and other solid tumors. The year ended with approximately $13.1 million in cash. Financially, the net loss for 2022 was $6.6 million, with a 50.8% increase in research and development expenses. A royalty payment of $1.7 million was received from a sublicense with Takeda, marking a 47.1% year-over-year increase.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced participation in the Virtual Investor NETs in Cancer Spotlight Event on March 29, 2023, at 11:00 AM ET. CEO Jeffrey Eisenberg, CSO Curtis Lockshin, and oncology leader Dr. Jonathan Spicer will discuss the Company's DNase-based oncology platform and the role of Neutrophil Extracellular Traps (NETs) in cancer. The event will feature a moderated roundtable discussion, enabling investors to submit questions live. A live video webcast will be available on Xenetic's website and archived for 90 days.